How Are Authorized Representative Responsibilities Allocated for Overseas Registration of Imaging Devices?

Key Summary

For imaging devices, the allocation of authorized representative responsibilities directly determines whether the registration process proceeds smoothly and affects post-market compliance and safety. Companies must first determine whether the target country regulates the imaging device as a medical device, then select the corresponding registration pathway based on product risk class, and confirm the legal applicant required by local law. The authorized representative typically carries statutory obligations such as communicating with regulatory authorities, receiving post-market vigilance reports, assisting in adverse event investigations, maintaining technical documentation, and renewing registration certificates. However, the precise scope of these responsibilities varies significantly across jurisdictions.

Companies should systematically review existing NMPA, CE, FDA, ISO 13485, or MDSAP documentation to assess which technical documents, performance validation studies, risk management reports, and clinical evidence can be reused and which require local adaptation. At the same time, quality system requirements, label and instruction language compliance, local agent changes, certificate control, and renewal mechanisms must be clarified. Common risks include authorized representatives lacking actual capability, ambiguous responsibility clauses, technical documentation insufficient to support local registration, and label/instructions conflicting with local regulations.

Through written agreements, companies should allocate responsibilities, establish an evidence chain, and implement post-market surveillance processes to reduce duplicate preparation and deficiency correction risks during multi-country registration. This article is compiled from the AIMEILI registration practice question bank, international medical device registration knowledge base, and public regulatory information; specific projects should be based on the latest requirements of the target country regulatory authority and the product documentation baseline.

Applicable Scenarios and Core Issues

When imaging device manufacturers plan to enter overseas markets, the authorized representative is an unavoidable element. Imaging devices include X-ray machines, ultrasound diagnostic equipment, CT, MRI, endoscopy systems, digital subtraction angiography systems, and associated software and accessories, including both active medical devices and supporting software and accessories. Different countries use different terms for the “authorized representative,” such as local representative, registration agent, or local license holder. Differences in name may reflect substantial differences in regulatory responsibility.

The authorized representative is essentially the statutory channel connecting the manufacturer to the target country’s regulatory authority. In most countries, an overseas manufacturer cannot directly submit a registration application and must designate a natural person or legal entity with a legal business address in the local market. The authorized representative is not a mailing address or a middle party that only stamps documents. In the European Union, Gulf states, and several Southeast Asian countries, the authorized representative bears responsibilities for regulatory compliance, post-market surveillance, and vigilance reporting. In other countries, the local agent may only be responsible for submitting documentation and receiving the registration certificate, but if a product safety issue arises, the regulatory authority will still contact that agent first.

Therefore, at the early stage of market entry, manufacturers must clarify a core question: what is the exact scope of the authorized representative’s responsibilities? Which tasks belong to the manufacturer, which to the authorized representative, and which require joint action? Relying on verbal agreements or template contracts can easily create responsibility gaps during deficiency corrections, product changes, complaint handling, and certificate renewal. For imaging devices, which are technically complex, often higher-risk, and used in special environments, the authorized representative must have sufficient technical understanding and regulatory capability to effectively respond to regulatory inquiries.

Another easily overlooked issue is that product classification determines the depth of the authorized representative’s work. Among imaging devices, some are medium or low risk, such as portable ultrasound diagnostic devices and general X-ray equipment, while others are high risk, such as implantable image-guided devices and imaging systems with therapeutic functions. Different risk classes correspond to different registration requirements and regulatory review intensity, as well as different demands on technical documentation, clinical evaluation, and quality management systems. Manufacturers must first determine whether the product falls within the target country’s medical device regulatory scope and confirm the registration pathway and applicant based on risk class. If this step is wrong, all subsequent authorized representative arrangements will be built on an incorrect foundation.

In multi-country registration, the authorized representative is not a single role. When entering GHWP member countries or simultaneously expanding into Southeast Asia, the Middle East, Latin America, and other markets, requirements may be independent or mutually recognized. Manufacturers should consider how to leverage existing CE or FDA registration documentation to reduce duplicate testing while meeting each country’s localization requirements. Authorized representative responsibility allocation should be tied to the overall registration strategy rather than decided on a country-by-country basis at the last minute.

Registration Determination Logic

When facing a specific target country, manufacturers should not simply copy the registration model from another market. The correct logic is stepwise.

• First, confirm whether the product is regulated as a medical device in that country. Some imaging devices may be classified as radiation devices, electronic medical equipment, or standalone health software. For example, software used solely for viewing DICOM images may be managed as software as a medical device, while imaging analysis software with AI-assisted diagnostic functions may change risk class and registration pathway.
• Second, determine the risk class. Most countries use risk-based classification, typically aligned with International Medical Device Regulators Forum (IMDRF) classification rules. Imaging devices generally fall into Class II or Class III, and some software may be classified as higher risk. Manufacturers should consult the official classification list of the target country or self-classify according to applicable regulations. Incorrect classification can not only make registration documentation insufficient but may also result in rejection or affect the compliance status of already marketed products.
• Third, confirm the registration pathway and applicant. Some countries require overseas manufacturers to have a local authorized representative submit the application, while others allow direct online submission by the manufacturer but require a local contact. In some countries, the registration certificate holder is the authorized representative; in others, it is the manufacturer. This is the starting point for responsibility allocation: whoever owns the certificate bears ongoing compliance responsibility. Manufacturers must confirm this legal structure with the authorized representative and local legal counsel before project initiation.
• Fourth, assess whether existing documentation can be reused. Imaging device manufacturers typically already hold NMPA registration, CE certificates, FDA 510(k) or PMA, and ISO 13485 or MDSAP certificates. These are important foundations for overseas registration. Performance validation, electrical safety testing, electromagnetic compatibility testing, risk management reports, and clinical evaluation in technical documentation are likely reusable across multiple countries. However, local technical standards and test report validity must be considered; some countries only recognize reports issued by national or specific accredited laboratories.
• Fifth, confirm localization requirements. Technical documentation may need translation into the local language, and labels and instructions for use must comply with local language and regulatory requirements. Some countries also require local clinical data or ethical review opinions. Quality system audit results may also require localization. Localization work is usually led by the manufacturer, but the authorized representative is responsible for communicating with the regulatory authority and explaining submitted materials. Responsibility allocation must be precise down to specific documents and approval milestones.
• Sixth, plan post-market maintenance. The authorized representative’s responsibilities do not end with registration approval. Product changes, annual updates, adverse event reporting, safety alerts, and certificate renewals all require continuous follow-up. Software updates and hardware modifications to imaging devices may trigger new registration obligations. The authorized representative must be informed in a timely manner and assist with filings. If the authorized representative is unaware of product changes, the regulatory authority will consider the manufacturer as having failed to fulfill reporting obligations, and liability will trace back directly to the manufacturer.

Documentation and Evidence

Allocation of authorized representative responsibilities cannot remain a paper agreement; it must be reflected in specific documentation and a chain of evidence. The first batch of documents is company registration documents, business registration certificates, and the authorized representative’s qualification proof. These documents prove that the authorized representative legally exists in the local country and has the legal capacity to receive regulatory notifications. Some countries require notarization or legalization of these documents, and some require apostille or consular authentication. Companies should prepare both English and local language versions in advance.

The second batch is the authorization letter or designation letter. The authorization letter must clearly specify the scope, including submitting registration applications, receiving registration certificates, receiving regulatory correspondence, cooperating with inspections, handling adverse event reports, applying for changes, and renewing certificates. The scope should not be overly broad; otherwise, it will be difficult to hold the authorized representative accountable for overstepping or refusing to cooperate. The validity period, termination clauses, and notification obligations in the authorization letter should also be clear.

The third batch is technical documentation. This is the most critical evidence for responsibility allocation. At a minimum, technical documentation for imaging devices includes product description, intended use, working principle, structural composition, specifications, software description, risk management documentation, performance validation, and clinical evaluation. Every item may be reviewed by the target country’s regulatory authority to verify product safety and effectiveness. If technical documentation is issued by a third-party testing organization outside the target country, confirmation is needed whether the report meets local acceptance requirements.

The fourth batch is quality management system documentation. An ISO 13485 certificate is the most common evidence; some countries accept MDSAP certificates or inspection records. Manufacturers should provide the scope of the quality system, especially whether design and production sites match the registration applicant. If imaging device production is outsourced, procurement control, supplier audits, and incoming inspection records must be provided. Quality system evidence demonstrates that the manufacturer can continuously meet regulatory requirements. The authorized representative is usually not responsible for the quality management system itself but must ensure that regulatory authorities can access the relevant information.

The fifth batch is labels and instructions for use. Different countries have varying requirements for warning statements, language, graphical symbols, and electronic instructions. Companies must provide complete label drafts and instructions in the target country’s language. Some countries require specific contraindication content, radiation protection information, or maintenance instructions. Missing content can cause prolonged deficiency corrections. The authorized representative should review labels and instructions to ensure local regulatory compliance, rather than relying solely on the manufacturer’s determination.

The sixth batch is post-market surveillance and adverse event reporting procedures. Companies should establish a global post-market surveillance database recording complaints, adverse events, recalls, and field safety corrective actions. The authorized representative needs access to this data and must submit reports to the regulatory authority within the legally required timeframe. When allocating responsibilities, it should be clear that the manufacturer is responsible for global data collection and analysis, while the authorized representative is responsible for notification and communication with the local regulatory authority.

In addition, the authorized representative must maintain a complete registration file. Even after a certificate is approved, the file must be continuously retained. Retention periods typically extend through the product lifecycle plus a certain number of years. Companies should agree with the authorized representative on the storage location and custodial responsibility to avoid loss of historical documents due to staff turnover or closure of the agency.

Common Errors

• Error 1: Assuming the authorized representative is merely a contact for document exchange and failing to define its regulatory responsibilities in the agreement. When the regulatory authority issues a safety alert or requires an urgent recall, the authorized representative may be unwilling or unauthorized to cooperate, leading to a compliance crisis.
• Error 2: Using the target country language version of the authorization letter but translating the scope inaccurately, such as mistranslating “receive registration certificate” as “own registration certificate,” causing certificate ownership disputes.
• Error 3: Ignoring local regulatory qualifications for authorized representatives. Some countries require the registration agent to be a locally licensed professional or consultant with professional liability insurance. Appointing an import/export trading company without such qualification can lead to immediate rejection of the registration application.
• Error 4: Directly copying NMPA submission files without converting them to the target country’s required format and language. Electrical safety and EMC reports for imaging devices are especially likely to be questioned by local laboratories.
• Error 5: Using English labels and instructions directly without considering local language, units of measure, warning icons, and imported country-specific contraindications. If the regulatory authority requires modifications, the registration timeline may be significantly extended.
• Error 6: Lacking a post-market surveillance mechanism. Without an established adverse event reporting process, the authorized representative does not know who to report to, and when a real complaint occurs, it is impossible to submit a report within the legal deadline.
• Error 7: Treating the authorized representative as a permanent service provider without provisions for change, termination, and transition. When the agent performs poorly or a distributor changes, the manufacturer may be forced to change representatives, but certificate ownership and registration file handover can become chaotic, causing the product to be withdrawn from sale.
• Error 8: Failing to plan multi-country registration as a whole. Signing separate agreements and preparing separate documentation for each country leads to high duplicate preparation and deficiency correction costs, and may result in inconsistent technical parameters submitted for the same product in different countries.

Company Preparation Checklist

• Confirm whether the target country regulates the imaging device as a medical device and complete product classification.
• Screen and verify the authorized representative’s qualifications, business scope, industry experience, and regulatory communication record, and obtain evidence of capability.
• Sign a bilingual authorization letter covering scope, term, termination clauses, confidentiality, and data access rights, and complete notarization and legalization.
• Establish a target country regulatory tracking mechanism and designate a dedicated person to monitor regulatory changes and update responsibility allocation.
• Organize NMPA, CE, FDA, ISO 13485, and MDSAP certificates and reports to build a reusable technical documentation library.
• Complete the drafting, translation, and proofreading of labels and instructions in the target country language, and retain version records.
• Establish a global adverse event reporting database and provide the authorized representative with read-only or on-demand access.
• Develop a certificate control plan that specifies the custodian of the original registration certificate, the change initiation process, and renewal deadlines.
• Create an annual authorized representative review sheet and assess service capability and compliance status each year.
• Work with local legal counsel to draft a responsibility matrix detailing leads and timelines for document submission, regulatory communication, inspection cooperation, and post-market reporting.

AIMEILI Regulatory Interpretation and Business Impact

Manufacturers most often make the mistake of viewing the authorized representative as a “registration outsourcing service provider” and assume that paying for the service ensures compliance. In reality, the authorized representative is only one link in the regulatory system; the ultimate compliance responsibility always lies with the manufacturer. Unclear responsibility allocation will ultimately harm the manufacturer itself. We strongly recommend that manufacturers complete a responsibility matrix before project initiation rather than waiting for a registration delay or a safety incident to force a supplemental agreement.

At the early stage, the most valuable action is to systematically evaluate the target market’s regulatory framework rather than rushing to find an agent. Confirm product classification, registration pathway, certificate ownership, and the statutory representative obligations defined by law before deciding on authorized representative selection criteria. This approach avoids substantial wasted effort. For companies entering multiple countries simultaneously, prioritize markets that can share technical documentation and have mutual recognition foundations, using one core set of documentation to support multi-country submissions and reduce duplicate preparation and deficiency correction risks.

Which documents can be reused? ISO 13485 certificates, risk management reports, electrical safety test reports, EMC test reports, software lifecycle documentation, and clinical evaluation reports are basic assets. Which documents must be localized? Labels and instructions for use, local registration application forms, local authorization letters, local-language risk management summaries, local clinical requirements, and imported-country-specific test reports. Companies should build a two-tier structure of a “global master technical file” plus a “country-specific difference checklist” so that entering a new market requires only supplementing the difference items.

Why are local agent changes, certificate control rights, and change/renewal processes important? Because these three factors directly determine whether a product can remain legally marketed. If the authorized representative stops cooperating or the agency goes out of business, the registration certificate may become invalid, and the product may have to stop sales. We recommend that the authorization agreement explicitly require the agent to periodically provide regulatory updates and that the manufacturer always retain the technical documentation and submission history for the registration certificate. Change and renewal processes should be initiated at least six months in advance, never waiting until the certificate expires to contact the agent.

In multi-country registration, duplicate preparation and deficiency correction risks mainly arise from version confusion, inconsistent translation, and incomplete understanding of local regulations. Companies need a document control procedure to ensure that technical documentation submitted to all countries remains consistent after each change. In addition, have the authorized representative participate in early document review rather than waiting for registration rejection to make corrections. This approach significantly shortens approval time and makes responsibility allocation clearer.

Common Follow-up Questions

Can a distributor or importer serve as the authorized representative?

Yes, but with caution. Some countries allow an importer to serve as the authorized representative. However, importers are often more focused on commercial interests and may invest limited resources in regulatory compliance. If the distributor simultaneously handles sales and registration representation, there is a risk of losing certificate ownership and registration files when the distributor changes. Companies should assess whether the distributor has regulatory capability and ensure in the agreement that registration representative duties are separated from sales activities, at least to the extent of independent file retention.

When changing an authorized representative, does the certificate need to be re-applied?

Rules vary by country. Some countries permit a change of registration agent through a change application and new authorization letter. Others require cancellation of the original certificate and re-registration. In either case, the manufacturer should prepare a complete set of registration files in advance for handover to the new authorized representative. It is advisable to include transition cooperation clauses in the agreement, such as requiring the previous authorized representative to transfer all original documents and regulatory account access.

Does a software update for an imaging device trigger the authorized representative’s reporting obligation?

It depends on whether the update affects safety or intended use. If it only fixes a non-safety bug, immediate reporting is usually not required, but it should be recorded in the post-market surveillance system. If the update introduces new features, changes algorithms, or expands the target population, it constitutes a significant change, and the authorized representative must submit a change application to the regulatory authority. Manufacturers should establish a software change assessment process and share the change timeline with the authorized representative to avoid missing filings.

How long must the authorized representative retain technical documentation?

Most countries require retention for at least the product lifecycle, and some require no less than five or ten years. Imaging devices have long lifecycles, so we recommend retaining documentation for at least ten years after the product stops being sold. Both the manufacturer’s global technical library and the authorized representative’s local file should meet this requirement. It is best to agree that when the agreement terminates, all documents must be returned to the manufacturer, with a complete handover record preserved.

Content Review and Applicability Boundary

Content author: AIMEILI Regulatory Editorial Board

Professional review: AIMEILI Medical Device International Registration Project Group

Source principle: Priority is given to official regulatory agencies, international organizations, standards organizations, and public regulatory materials; industry media and project experience are used only as auxiliary references.

Applicability boundary: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace official requirements, testing conclusions, or legal opinions of target country regulatory authorities.